EGFR and glioblastoma: The stimulated p300 activity enriches H3K27ac at the KAT7 promoter, thereby inducing KAT7-targeting genes that are critical for EGFR-driven GBM tumorigenesis and enhancing GBM response to anti-EGFR therapies.